Cellara builds programmable cell and gene therapy platforms — from target discovery through clinical translation — for diseases with no durable treatment today.
Cellara's vector-design engine generates and screens thousands of candidate constructs computationally before a single one reaches the bench — cutting years off the traditional discovery timeline. Drag the model to inspect the structure.
AAV9 capsid delivering a functional gene copy to retinal pigment epithelium
Autologous CAR-T cells targeting a B-cell surface antigen
Lipid-nanoparticle mRNA restoring enzyme expression in hepatocytes
Ex vivo lentiviral correction of muscle progenitor cells
Allogeneic iPSC-derived NK cells engineered for tumor infiltration
Oral small molecule modulating pre-mRNA splicing
Liver-tropic AAV delivering a clotting factor transgene
Self-amplifying RNA platform for a single-dose prophylactic
Expanded tumor-infiltrating lymphocytes with cytokine support
Bifunctional degrader targeting an intracellular signaling node
Cellara was founded to close the gap between computational vector design and clinical translation — the platform, the manufacturing, and the trial operations all live under one roof.
Meet the teamWe keep molecular targets confidential pre-patent, but we try to be transparent about the mechanism class…
Cell therapy's biggest bottleneck isn't the science. It's turning a bespoke, patient-specific product into something repeatable.
A failed dose-escalation cohort taught us more about manufacturing variability than any of our successes did.